PMID- 22642440 OWN - NLM STAT- MEDLINE DCOM- 20140115 LR - 20220409 IS - 1743-6109 (Electronic) IS - 1743-6095 (Linking) VI - 9 IP - 8 DP - 2012 Aug TI - Therapeutic effect of adipose-derived stem cells and BDNF-immobilized PLGA membrane in a rat model of cavernous nerve injury. PG - 1968-79 LID - 10.1111/j.1743-6109.2012.02760.x [doi] AB - INTRODUCTION: Cavernous nerve injury is the main reason for post-prostatectomy erectile dysfunction (ED). Stem cell and neuroprotection therapy are promising therapeutic strategy for ED. AIM: To evaluate the therapeutic efficacy of adipose-derived stem cells (ADSCs) and brain-derived neurotrophic factor (BDNF) immobilized Poly-Lactic-Co-Glycolic (PLGA) membrane on the cavernous nerve in a rat model of post-prostatectomy ED. Methods. Rats were randomly divided into five groups: normal group, bilateral cavernous nerve crush injury (BCNI) group, ADSC (BCNI group with ADSCs on cavernous nerve) group, BDNF-membrane (BCNI group with BDNF/PLGA membrane on cavernous nerve) group, and ADSC/BDNF-membrane (BCNI group with ADSCs covered with BDNF/PLGA membrane on cavernous nerve) group. BDNF was controlled-released for a period of 4 weeks in a BDNF/PLGA porous membrane system. MAIN OUTCOME MEASURES: Four weeks after the operation, erectile function was assessed by detecting the ratio of intra-cavernous pressure (ICP)/mean arterial pressure (MAP). Smooth muscle and collagen content were determined by Masson's trichrome staining. Neuronal nitric oxide synthase (nNOS) expression in the dorsal penile nerve was detected by immunostaining. Phospho-endothelial nitric oxide synthase (eNOS) protein expression and cyclic guanosine monophosphate (cGMP) level of the corpus cavernosum were quantified by Western blotting and cGMP assay, respectively. RESULTS: In the ADSC/BDNF-membrane group, erectile function was significantly elevated, compared with the BCNI and other treated groups. ADSC/BDNF-membrane treatment significantly increased smooth muscle/collagen ratio, nNOS content, phospho-eNOS protein expression, and cGMP level, compared with the BCNI and other treated groups. CONCLUSIONS: ADSCs with BDNF-membrane on the cavernous nerve can improve erectile function in a rat model of post-prostatectomy ED, which may be used as a novel therapy for post-prostatectomy ED. CI - (c) 2012 International Society for Sexual Medicine. FAU - Piao, Shuyu AU - Piao S AD - Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea. FAU - Kim, In Gul AU - Kim IG FAU - Lee, Ji Young AU - Lee JY FAU - Hong, Sung Hoo AU - Hong SH FAU - Kim, Sae Woong AU - Kim SW FAU - Hwang, Tae-Kon AU - Hwang TK FAU - Oh, Se Heang AU - Oh SH FAU - Lee, Jin Ho AU - Lee JH FAU - Ra, Jeong Chan AU - Ra JC FAU - Lee, Ji Youl AU - Lee JY LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120529 PL - Netherlands TA - J Sex Med JT - The journal of sexual medicine JID - 101230693 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Immobilized Proteins) RN - 0 (Membranes, Artificial) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - 26009-03-0 (Polyglycolic Acid) RN - 33X04XA5AT (Lactic Acid) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type I) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type III) RN - H2D2X058MU (Cyclic GMP) SB - IM MH - Adipocytes/cytology/*transplantation MH - Animals MH - Brain-Derived Neurotrophic Factor/*administration & dosage MH - Cyclic GMP/pharmacology MH - Erectile Dysfunction/drug therapy/surgery/*therapy MH - Humans MH - Immobilized Proteins/*administration & dosage MH - Lactic Acid/*administration & dosage/chemistry MH - Male MH - *Membranes, Artificial MH - Nerve Crush/methods MH - Nitric Oxide Synthase Type I/biosynthesis MH - Nitric Oxide Synthase Type III/biosynthesis MH - Penis/innervation/surgery MH - Polyglycolic Acid/*administration & dosage/chemistry MH - Polylactic Acid-Polyglycolic Acid Copolymer MH - Prostatectomy/adverse effects MH - Pudendal Nerve/enzymology MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - Stem Cell Transplantation/*methods EDAT- 2012/05/31 06:00 MHDA- 2014/01/16 06:00 CRDT- 2012/05/31 06:00 PHST- 2012/05/31 06:00 [entrez] PHST- 2012/05/31 06:00 [pubmed] PHST- 2014/01/16 06:00 [medline] AID - S1743-6095(15)34052-2 [pii] AID - 10.1111/j.1743-6109.2012.02760.x [doi] PST - ppublish SO - J Sex Med. 2012 Aug;9(8):1968-79. doi: 10.1111/j.1743-6109.2012.02760.x. Epub 2012 May 29.